E.U. Expands Antitrust Review Of Guidant Deal

Law360, New York (March 27, 2006, 12:00 AM EST) -- As feared by industry observers, the European Commission chose Monday to expand its antitrust inquiry into the long-awaited acquisition of medical device maker Guidant Corp. by rival Boston Scientific Corp.

The delay will cost Boston Scientific tens of millions of dollars. The company had held out hopes of completing the deal by March 30, but conceded that might change after the company made certain commitments to the Commission last week.

The commitments were intended to alleviate the Commission's antitrust concerns.

The Commission’s announcement has pushed the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.